News
Xeltis has reported positive preliminary data for its Xabg coronary artery bypass conduit (CABG) in a trial that is underway at EU sites.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback